According to the results of the ZUMA-7 clinical trial, the CAR T-cell therapy Yescarta (axicabtagene ciloleucel) is significantly more effective than the current standard of care in treating people with large B-cell lymphoma who relapse after the first line of treatment.
The Harrington Discovery Institute at University Hospitals and the American Society for Clinical Investigation have awarded Owen Witte with the twelfth annual Harrington Prize for Innovation in Medicine.
